Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently Oncogeni, which has developed two families of innovative cell and RNA oncology medicines.